Trial Profile
Pilot Study of ORG 25935 Modulation of Ketamine-Induced Behavioral and Cognitive Effects in Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs ORG 25935 (Primary) ; Ketamine
- Indications Schizophrenia
- Focus Pharmacodynamics
- 02 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 07 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.